for you call. financial and conference TRACON's third will recent our pipeline begin with activities. thank results and quarter business and afternoon, joining Good on update I XXXX an update
Scott months Following the Brown, September Chief that, Officer, will for nine Accounting financial three our XXXX. and ended review XX, results our
Finally, conclude will by we taking your questions.
centered Our to three continue efforts be on value propositions.
continue a to First, of we develop clinical stage assets. pipeline robust
clinical Second, tracking in are of of the XXXX. IMF's pipeline intent multiple for preclinical selecting at we of development progress antibodies one with the biospecific least of assets these
external that assets our significant evaluate expertise. U.S. potentially key drive and Third, long-term to to in us to will platform to leverage We shareholder new XXXX our continue our development and establish partnerships we development includes continue clinical that product stage platform pipeline value. will XXXX product to commercialization allow believe independent additional CRO add
clinical providing an clinical Let's cash four to this by If at runway important we data financial resources begin we XXXX our for facility extend of into points transaction us time with which Capital at the each estimate sale. prices our utilized, with the into QX XXXX, remains significant would of fully to with requests continue time registration in at $XX follower establish entered development leverage related best-in-class We to assets. Aspire development, financial and the new Aspire a goal our platform. committed on million With the date or or statement during product and partnerships fast corporate to to the purchase a time about respect October. XX stage stock the first-in-class, market to business around financial our flexibility to TRACON's up executed of an effective from agreement common based on month period price beginning to transaction
four with the unmet Let's assets of there experience inhibitors, ophthalmic improved essential like to VEGF in we combination begin a believe stage carotuximab. with Because AMD. to not patients agents formulation VEGF substantial meaningfully wet target do is treatment turn our vision be need and majority now upon endoglin, angiogenetic the that clinical DE-XXX, for clinical with pathways, inhibitors in single-agent developed of
randomized single-agent Lucentis with doses Our compares completed three-arm Lucentis. Phase licensee, with that in different Santen, last to AVANTE two treatment enrollment with combined DE-XXX treatment quarter study the II of
U.S. six The XX patients milestone data, clinical of in trial the visual in expected XXXX. expected at sites significant be the is This endpoint first-half our of the months first are to accrued acuity XXXX. corrected best following including and primary dosing of top of line
to financial success milestones significant $XXX low including a high sales. in and regulatory, net DE-XXX, teen retains remaining based to on TRACON global million developmental, royalty rights and commercialization single-digit
cell reverse a focused DNA on NCI repair to resistance that now or four is Phase the that to Phase second TRCXXX, mesothelioma I stage the novel, trials lung non-small is turn to of chemotherapeutics. small-molecule asset by sponsored excision in that We'll intended base are clinical patients continues pathway II Enrollment cancer. certain inhibitor with or our
in TRCXXX with that response. ongoing gene Phase from well to correlates patients as glioblastoma tumor As specimens from specimens trials II well, with goal the profile identifying a biomarkers tumor as continue in expression our clinical academic trial, collaborators in protein completed treated of evaluate or the
clinical We presentations TRCXXX XXXX. in on expect multiple data
another more month, to XX studying sufficient Xtandi cancer prostate prostate with resistance FXXXL we or receptor profile a another basis trial or to Earlier in that patients: those determine have Erleada. to with We'll those those in risk-benefit Erleada. treatment asset for than now move Xtandi clinical third with mutation, with enrolled with I/II TRCXXX on patients Janssen an androgen resistance are developed our stage TRCXXX, who this three we're mutation, of cancer, to acquired agreed in patients Phase castrate-resistant with metastatic undisclosed of the point cohorts and that
andro indicate While lower and mature, mutation. and therapy the available not patients the data early initial with the lower to of in prevalence that expected response than data than expected a rate mutation FXXXL receptor
they II Phase million in in II independently payment, not Janssen $XXX.X the if on we low entitled a data, right the to of TRACON to enrolled from re-acquire proof-of-concept half sales. completion the TRCXXX to TRACON opt-in to patients is a success-based their to Janssen upfront TRACON partner and currently the the on can data receive If Based all accrual, up expect now license Jansen on first XXXX. Phase does from TRCXXX royalty of million a proof-of-concept exercise deliver or in that and opt-in, Recall and asset single-digit advance with abroad. milestones $XX U.S.
a and developing in marketed first from Our this trial and presenting X in top is half fourth the supplied of completing by we escalation studied TJXXXXXX and Through I-Mab TJXXXXXX, second anticipate being X We're with PD-LX dose collaboration Roche. our with is in Phase line antibody XXXX. antibody study clinical agreement which agent Biopharma. dose in them being single as Phase with combination the escalation CDXX a asset stage Tecentriq, a data
a of of in TRACON collaboration, is and the and And out U.S. development payments, TJXXXXXX to Europe. responsible portions party. this if the escalating TJXXXXXX I-Mab TRACON elect In and royalty for is clinical non-royalty regulatory to third license
a multi-product tumors exciting agreement believe to that approaches hot to T-cells that for second to bispecific is We most the cancer potential have micro I-Mab's America. make words in tumor of with direct North bispecific collaboration environment, antibodies, or antibodies cold five to in up therapeutic those especially the the treatments. other Our to one develop I-Mab
advancing At innovation. has time, source their continued our Further, access of I-Mab antibodies. pipeline multiproduct a this we disclosed as view bispecific preclinical to a viable seven
bispecifics expression of I-Mab one an the in including the targets PD-LX XXBB interested associated engage through through tumor expression that receptor, T-cells targets another T-cell undisclosed particularly that tumor and the that antigen. tumor through the are We
For clinical U.S. U.S. to the for from will trials. subject bear the share of will I-Mab the commercialization companies and and for in the phase more U.S. will collaboration. TRACON any cost and bispecific costs lead development development and and share clinical TRACON becomes early commercialization also commercialization. equally two antibody the stages profits advanced in
TRACON's element collaboration becomes study. of from Another to in prior is right each the license any to at pivotal that bispecific worth conclusion the agreement subject time this to antibody of noting I-Mab
Greater escalate to reflect opt-in all development. phase would payments of the China. The territories option advancing this Exercising expand rights our include outside of
an due of IND exercises its to example, option $XX payment For opt-in to studies. million prior enabling is TRACON
the an IND the in first I-Mab XXXX. bispecific antibody file U.S. We from in expect to for
XXXX currently From fund the of our our resources expected potential operations clinical third through financial perspective, milestones. bad capital quarter our planned sufficient development and creating be into multiple are to and to business
our discussed through rate equity Capital. we the with further be of line Aspire established run use extended recently may As
At Scott this time, our update on will financial provide an financials.
